Myung In Pharmaceutical LTD. (KRX:317450)

KRX:317450 Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	47,729	32,897	34,449	18,251	52,967	70,504
Short-Term Investments	230,137	227,399	153,080	124,434	67,786	183
Cash & Short-Term Investments	277,866	260,296	187,529	142,686	120,753	70,687
Cash Growth	94.74%	38.80%	31.43%	18.16%	70.83%	12.19%
Accounts Receivable	62,512	60,771	58,147	56,783	56,688	57,571
Other Receivables	4,225	3,492	3,711	2,710	2,138	2,231
Receivables	66,899	64,433	62,020	59,646	59,033	60,068
Inventory	59,636	60,343	56,277	47,880	46,732	44,057
Prepaid Expenses	583.29	510.71	434.13	533.52	243.22	253.98
Other Current Assets	397.17	225.49	1,329	72.68	176.49	72.08
Total Current Assets	405,381	385,809	307,589	250,818	226,938	175,138
Property, Plant & Equipment	105,208	99,259	99,309	103,706	110,187	151,957
Long-Term Investments	11,206	10,783	28,608	24,242	6,804	889.1
Other Intangible Assets	4,079	713.02	710.9	711.01	711.69	1,052
Long-Term Accounts Receivable	1,998	2,231	2,039	2,300	2,545	2,364
Long-Term Deferred Tax Assets	-	-	-	-	4.51	4.35
Other Long-Term Assets	82,310	82,717	83,119	89,528	82,344	51,546
Total Assets	610,406	581,692	521,590	471,556	429,760	383,032
Accounts Payable	7,371	8,298	2,397	2,129	2,245	2,008
Accrued Expenses	1,236	1,327	1,425	1,296	2,290	1,613
Current Portion of Leases	1,629	1,528	1,727	1,739	1,329	1,412
Current Income Taxes Payable	12,016	12,389	12,949	11,472	13,494	9,157
Other Current Liabilities	24,728	21,059	20,686	18,458	20,374	22,829
Total Current Liabilities	46,993	44,602	39,184	35,093	39,732	37,019
Long-Term Leases	468.72	1,172	2,160	3,206	4,281	5,534
Long-Term Unearned Revenue	35.65	70.23	115.85	161.47	-	-
Long-Term Deferred Tax Liabilities	778.89	1,439	5,327	6,684	6,605	6,637
Other Long-Term Liabilities	1,546	2,589	2,489	2,432	2,382	1,335
Total Liabilities	49,828	49,871	49,276	47,577	53,668	52,609
Common Stock	5,600	5,600	5,600	5,600	5,600	5,600
Retained Earnings	561,701	533,269	471,701	421,245	373,297	327,627
Comprehensive Income & Other	-6,723	-7,049	-4,988	-2,866	-2,805	-2,805
Shareholders' Equity	560,578	531,821	472,314	423,979	376,092	330,423
Total Liabilities & Equity	610,406	581,692	521,590	471,556	429,760	383,032
Total Debt	2,098	2,700	3,887	4,945	5,609	6,946
Net Cash (Debt)	275,768	257,596	183,642	137,740	115,143	63,741
Net Cash Growth	100.21%	40.27%	33.32%	19.63%	80.64%	2.87%
Net Cash Per Share	24622.15	22999.63	16396.62	12298.25	10280.65	5691.17
Filing Date Shares Outstanding	11.2	11.2	11.2	11.2	11.2	11.2
Total Common Shares Outstanding	11.2	11.2	11.2	11.2	11.2	11.2
Working Capital	358,388	341,207	268,406	215,724	187,206	138,119
Book Value Per Share	50051.57	47483.98	42170.89	37855.28	33579.64	29502.05
Tangible Book Value	556,499	531,108	471,603	423,268	375,380	329,371
Tangible Book Value Per Share	49687.38	47420.31	42107.41	37791.80	33516.10	29408.15
Land	39,467	39,467	39,089	37,098	36,955	67,520
Buildings	59,273	59,179	59,291	59,020	58,923	62,627
Machinery	98,287	95,865	90,304	87,403	85,970	83,833
Construction In Progress	14,330	5,236	1,374	258.5	286.44	284

Source: S&P Global Market Intelligence. Standard template. Financial Sources.